The U.S. Food and Drug Administration (USFDA) has finally granted GlaxoSmithKline's Hiberix vaccine for children to prevent disease caused by Haemophilus influenzae type b.

The London-based drugmaker has received accelerated approval from the US FDA (Food and Drug Administration) for Hiberix Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) as a booster dose in children 15 months through four years of age.

Reports suggest that GlaxoSmithKline got accelerated approval for Hiberix because there was not enough of the vaccine in the market. The vaccine is expected to be available within several weeks.

The vaccine targets the bacterial infection known as Hib, which can cause meningitis, pneumonia, and other deadly illnesses.